Cullinan Oncology Announces Updated Phase 1/2a Data For CLN-081 In NSCLC EGFR Exon 20 Patients; Co. Reports 'Continued high response rate with favorable safety and tolerability profile observed in heavily pre-treated patients at 100mg BID'